External beam radiation therapy for clinically localized prostate cancer: When and how we optimize with concurrent hormonal deprivation

Archivos Espanoles de Urologia

Volumn 64, Issue 8, 2011, Pages 858-864

  Koontz, Bridget F ^a   Robert Lee, W ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

ADT; Androgen deprivation; Clinical trials; Prostate cancer; Radiotherapy

Indexed keywords

ANDROGEN; ANTIANDROGEN; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; GONADORELIN;

ADENOCARCINOMA; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; CLINICAL TRIAL (TOPIC); DRUG POTENTIATION; FOLLOW UP; HUMAN; MALE; MEGAVOLTAGE RADIOTHERAPY; MULTICENTER STUDY (TOPIC); MULTIMODALITY CANCER THERAPY; NEOPLASM; PATHOLOGY; PROSTATE TUMOR; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK; STATISTICS; TREATMENT OUTCOME;

ADENOCARCINOMA; ANDROGEN ANTAGONISTS; ANDROGENS; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; FOLLOW-UP STUDIES; GONADOTROPIN-RELEASING HORMONE; HUMANS; MALE; MULTICENTER STUDIES AS TOPIC; NEOADJUVANT THERAPY; NEOPLASMS, HORMONE-DEPENDENT; PROSTATIC NEOPLASMS; RADIOTHERAPY, HIGH-ENERGY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK; TREATMENT OUTCOME;

EID: 80055013428     PISSN: 00040614     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (31)

1. Huggins CB, R. E. Stearns Jr, and C. V. Hodges. Studies on prostatic cancer: II. the effects of castration on advanced carcinoma of the prostate gland. Arch Surg. 1941;43(2):209-223.
2. Vaillancourt LMD, Tetu BMD, Fradet YMD, et al. Effect of Neoadjuvant Endocrine Therapy (Combined Androgen Blockade) on Normal Prostate and Prostatic Carcinoma: A Randomized Study. American Journal of Surgical Pathology. 1996;20(1):86-93.
3. Westin P, Stattin P, Damber JE, Bergh A. Castration therapy rapidly induces apoptosis in a minority and decreases cell proliferation in a majority of human prostatic tumors. Am J Pathol. Jun 1995;146(6):1368-1375.
4. Joon DL, Hasegawa M, Sikes C, et al. Supraadditive apoptotic response of R3327-G rat prostate tumors to androgen ablation and radiation. Int J Radiat Oncol Biol Phys. Jul 15 1997;38(5):1071-1077. (Pubitemid 27353688)
5. Kaminski JM, Hanlon AL, Joon DL, Meistrich M, Hachem P, Pollack A. Effect of sequencing of androgen deprivation and radiotherapy on prostate cancer growth. Int J Radiat Oncol Biol Phys. Sep 1 2003;57(1):24-28. (Pubitemid 36959735)
6. Zietman AL, Nakfoor BM, Prince EA, Gerweck LE. The effect of androgen deprivation and radiation therapy on an androgen-sensitive murine tumor: an in vitro and in vivo study. Cancer J Sci Am. Jan-Feb 1997;3(1):31-36.
7. Johnke RM, Edwards JM, Evans MJ, et al. Circulating cytokine levels in prostate cancer patients undergoing radiation therapy: influence of neoadjuvant total androgen suppression. In Vivo. Sep-Oct 2009;23(5):827-833.
8. Laverdiere J, Gomez JL, Cusan L, et al. Beneficial effect of combination hormonal therapy administered prior and following external beam radiation therapy in localized prostate cancer. Int J Radiat Oncol Biol Phys. Jan 15 1997;37(2):247-252. (Pubitemid 27138705)
9. Widmark A, Klepp O, Solberg A, et al. Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial. Lancet. Jan 24 2009;373(9660):301-308.
10. Bolla M, Gonzalez D, Warde P, et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med. Jul 31 1997;337(5):295-300. (Pubitemid 27318990)
11. Bolla M, Collette L, Blank L, et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet. Jul 13 2002;360(9327):103-106.
12. Pilepich MV, Winter K, Lawton CA, et al. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma-long-term results of phase III RTOG 85-31. Int J Radiat Oncol Biol Phys. Apr 1 2005;61(5):1285-1290. (Pubitemid 40470408)
13. Pilepich MV, Winter K, John MJ, et al. Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys. Aug 1 2001;50(5):1243-1252. (Pubitemid 32727802)
14. Roach M, 3rd, Bae K, Speight J, et al. Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610. J Clin Oncol. Feb 1 2008;26(4):585-591. (Pubitemid 351264352)
15. D'Amico AV, Manola J, Loffredo M, Renshaw AA, DellaCroce A, Kantoff PW. 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial. Jama. Aug 18 2004;292(7):821-827. (Pubitemid 39079668)
16. D'Amico AV, Chen MH, Renshaw AA, Loffredo M, Kantoff PW. Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial. Jama. Jan 23 2008;299(3):289-295. (Pubitemid 351159365)
17. Denham JW, Steigler A, Lamb DS, et al. Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial. Lancet Oncol. Nov 2005;6(11):841-850. (Pubitemid 41614795)
18. Hanks GE, Pajak TF, Porter A, et al. Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92-02. J Clin Oncol. Nov 1 2003;21(21):3972- 3978. (Pubitemid 46606211)
19. Horwitz EM, Bae K, Hanks GE, et al. Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer. J Clin Oncol. May 20 2008;26(15):2497-2504.
20. Bolla M, de Reijke TM, Van Tienhoven G, et al. Duration of androgen suppression in the treatment of prostate cancer. N Engl J Med. Jun 11 2009;360(24):2516-2527.
21. Roach M, 3rd, DeSilvio M, Lawton C, et al. Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: Radiation Therapy Oncology Group 9413. J Clin Oncol.May 15 2003;21(10):1904-1911. (Pubitemid 46606377)
22. Lawton CA, DeSilvio M, Roach M, 3rd, et al. An update of the phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: updated analysis of RTOG 94-13, with emphasis on unexpected hormone/radiation interactions. Int J Radiat Oncol Biol Phys. Nov 1 2007;69(3):646-655. (Pubitemid 47418390)
23. Dearnaley DP, Sydes MR, Graham JD, et al. Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial. Lancet Oncol. Jun 2007;8(6):475-487. (Pubitemid 46805903)
24. Higano CS. Side effects of androgen deprivation therapy: monitoring and minimizing toxicity. Urology. Feb 2003;61(2 Suppl 1):32-38. (Pubitemid 36349540)
25. Stone P, Hardy J, Huddart R, A'Hern R, Richards M. Fatigue in patients with prostate cancer receiving hormone therapy. Eur J Cancer. Jun 2000;36(9):1134-1141. (Pubitemid 30330912)
26. van Andel G, Kurth KH. The impact of androgen deprivation therapy on health related quality of life in asymptomatic men with lymph node positive prostate cancer. Eur Urol. Aug 2003;44(2):209-214. (Pubitemid 36917005)
27. Keating NL, O'Malley AJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol. Sep 20 2006;24(27):4448-4456. (Pubitemid 46630983)
28. Tsai HK, D'Amico AV, Sadetsky N, Chen MH, Carroll PR. Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality. J Natl Cancer Inst. Oct 17 2007;99(20):1516-1524. (Pubitemid 351767235)
29. Kucway R, Vicini F, Huang R, Stromberg J, Gonzalez J, Martinez A. Prostate volume reduction with androgen deprivation therapy before interstitial brachytherapy. J Urol. Jun 2002;167(6):2443-2447. (Pubitemid 34533142)
30. Koontz BF, Chino J, Lee WR, et al. Morbidity and prostate-specific antigen control of external beam radiation therapy plus low-dose-rate brachytherapy boost for low, intermediate, and high-risk prostate cancer. Brachytherapy. Apr-Jun 2009;8(2):191-196.
31. Stock RG, Cahlon O, Cesaretti JA, Kollmeier MA, Stone NN. Combined modality treatment in the management of high-risk prostate cancer. Int J Radiat Oncol Biol Phys. Aug 1 2004;59(5):1352-1359. (Pubitemid 38954057)